Onconetix Subsidiary Proteomedix AG Announces Two New Publications Supporting Clinical Utility Of Proclarix To Reduce Overdiagnosis And Unnecessary Biopsies; Proteomedix Initiates Study For U.S. Market Viability Of Proclarix